Healthcare entity
Of the tracked stories, 4 of 4 also mention Eli Lilly, the most common co-covered peer. That works out to roughly 1.4 stories per week across a 20-day span. The busiest single day carried 2. Source depth averages 8 original sources per story, versus 3.1 across the same-window beat baseline.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 4 of 4 also mention Eli Lilly, the most common co-covered peer. That works out to roughly 1.4 stories per week across a 20-day span. The busiest single day carried 2. Source depth averages 8 original sources per story, versus 3.1 across the same-window beat baseline. Their average consequence score of 6.8 runs above the beat's 6 for that window. market-trends accounts for 2 of the 4 tracked stories, while 1 other category carries the remainder. tirzepatide appears in 4 tracked Healthcare stories published from March 4, 2026 through March 23, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 441 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering tirzepatide. Shared-story counts are live from our verified record — not editorial picks.
JPM Q1 Earnings Report
JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
FDA Orforglipron Decision
Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
Impurity Discovery
Lilly announces discovery of impurities in compounded samples and issues safety warnings.
Shortage Resolution
Expected timeframe for tirzepatide to be removed from FDA shortage list, ending legal compounding.
Impurity Warning
Lilly issues formal warning after testing reveals bacterial contamination in compounded samples.
Initial Lawsuits
Lilly begins filing legal actions against medspas for trademark infringement.
Shortage Surge
Widespread shortages lead to a massive increase in compounding pharmacy production.
Zepbound Approval
FDA approves Zepbound for chronic weight management.
Shortage Begins
FDA adds tirzepatide to the official drug shortage list, enabling compounding.
Mounjaro Approval
FDA approves Mounjaro for Type 2 diabetes treatment.
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Source: Adria Cimino (us) · fool.com
Eli Lilly has issued a formal warning regarding the discovery of impurities in compounded versions of its popular weight-loss treatments. The pharmaceutical giant highlighted significant safety risks associated with these unapproved alternatives, which have proliferated during ongoing supply shortages.
Eli Lilly has issued a formal warning after discovering impurities in compounded versions of its blockbuster weight-loss medication. The pharmaceutical giant cautioned that these unapproved formulations pose significant health risks to patients seeking alternatives during supply shortages.
Source: gdnonline.com · gdnonline.com
Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure. Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions.
Source: Prosper Junior Bakiny (us) · Keithen Drury (us)
tirzepatide is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
